title: Multi-low-dose mucosal simian immunodeficiency virus SIVmac239 challenge of cynomolgus macaques immunized with "hyperattenuated" SIV constructs.
abstract: Hyperattenuated simian immunodeficiency virus SIVmac239-derived constructs Delta5-CMV and Delta6-CCI are an effort to render SIV incapable of, in practical terms, both reversion and recombination while maintaining the immune features of SIV as a retrovirus. Primary inoculation of cynomolgus macaques with 10(8) 50% tissue culture infective doses (TCID(50)) of Delta5-CMV or Delta6-CCI induced low-level humoral and cellular responses detectable in the absence of measureable in vivo replication. The first of three DNA boosts resulted in elevated gamma interferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) responses to Gag, Pol, and Env in the Delta5-CMV vaccine group compared to the Delta6-CCI vaccine group (P = 0.001). Weekly intrarectal challenge with a low dose of SIVmac239 followed by a dose escalation was conducted until all animals became infected. The mean peak viral load of the Delta5-CMV-vaccinated animals (3.7 x 10(5) copies/ml) was approximately 1 log unit lower than that of the control animals. More dramatically, the viral load set point of these animals was decreased by 3 log units compared to that of the controls (<50 versus 1.64 x 10(4) copies/ml; P < 0.0001). Seventy-five percent (6/8) of vaccine recipients controlled virus below 1,000 copies/ml for at least 6 months, with a subset controlling virus and maintaining substantial CD4 T-cell counts for close to 2 years of follow-up. The correlates of protection from SIV disease progression may lie in the rapidity and protective value of immune responses that occur early in primary SIV infection. Prior immunization with hyperattenuated SIVmac239, even if sterilizing immunity is not achieved, may allow a more advantageous host response.
authors.affiliation: Department of Microbiology, Mt. Sinai Hospital, Ontario, Canada.
authors.forename: David O
authors.initials: DO
authors.lastname: Willer
authors.forename: Yongjun
authors.initials: Y
authors.lastname: Guan
authors.forename: Mark A
authors.initials: MA
authors.lastname: Luscher
authors.forename: Bing
authors.initials: B
authors.lastname: Li
authors.forename: Rick
authors.initials: R
authors.lastname: Pilon
authors.forename: Jocelyn
authors.initials: J
authors.lastname: Fournier
authors.forename: Monique
authors.initials: M
authors.lastname: Parenteau
authors.forename: Mark A
authors.initials: MA
authors.lastname: Wainberg
authors.forename: Paul
authors.initials: P
authors.lastname: Sandstrom
authors.forename: Kelly S
authors.initials: KS
authors.lastname: MacDonald
mesh_terms: D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000235:genetics / Q000276:immunology*; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006801:Humans; D007371:Interferon-gamma / Q000276:immunology; D008214:Lymphocytes / Q000166:cytology / Q000276:immunology; D008252:Macaca fascicularis / Q000276:immunology / Q000821:virology; D008297:Male; D012367:RNA, Viral / Q000097:blood / Q000235:genetics / Q000276:immunology; D018449:SAIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000503:physiopathology / Q000517:prevention & control* / Q000821:virology; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology*; D014611:Vaccination / Q000379:methods; D014766:Viremia
chemical_list: D012367:RNA, Viral; D018449:SAIDS Vaccines; D007371:Interferon-gamma; D016282:Aspartic Acid Endopeptidases; C077164:SIV(mac) proteinase